PlateletBio
United States
- Watertown, Massachusetts
- 04/11/2021
- Series B
- $75,500,000
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a superior cell therapy empowered to tackle previously unmet medical challenges.
- Industry Biotechnology Research
- Website https://www.plateletbio.com/
- LinkedIn https://www.linkedin.com/company/platelet-biogenesis/about/
Related People
Sam RastyFounder
United States -
Greater Boston
Biotech CEO with 25+ years of experience in leadership roles of increasing responsibility spanning global large pharma, mid-cap pharma and small, private biotech. Success in start-up company formation and launch, strategy formulation, fund raising, operations, R&D, manufacturing, corporate development, BD&L and M&A. Strategic and operational leader with product development experience in multiple therapeutic areas and technology platforms spanning small molecules to biologics to more complex gene and cell therapies.
EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)